Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03723447 · ClinicalTrials.gov registry record · Phase 4

Intraoperative TAP Block With Bupivacaine/Dexamethasone Against Liposomal Bupivacaine (Exparel®)

A Phase 4 study of Colorectal Cancer and Pain, sponsored by Cedars-Sinai Medical Center.

Completed
Registry status
Phase 4
Development phase
102
Enrollment target
1
Study location

NCT03723447: Completed Phase 4 study of Colorectal Cancer and Pain, sponsored by Cedars-Sinai Medical Center.

NCT03723447 is a Phase 4 study of Colorectal Cancer and Pain that has completed, run by Cedars-Sinai Medical Center. The registered enrollment target is 102 participants, below the 1,544-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03723447, a Phase 4 study of Colorectal Cancer and Pain, has completed, sponsored by Cedars-Sinai Medical Center.

COMPLETED
Registry status
Phase 4
Development phase
102 participants
Enrollment target
1
Study location

Study Summary

Traditionally, opioids are heavily utilized in treating postoperative pain but they are associated with numerous side effects. The use of the transversus abdominis plane (TAP) blocks have become standard practice to extend the post-operative analgesic window and limit opioid use. A new liposomal-depo formulation of bupivacaine (Exparel) has gained popularity as a long-lasting TAP block medication, but has not been studied in a well-powered clinical trial specifically in colorectal patients nor compared to a bupivacaine/steroid mixture which may offer similar effects. We conduct a prospective randomized prospective randomized study of patients undergoing major laparoscopic colorectal surgery to compare the analgesic effects of a bupivacaine/steroid mixture versus liposomal bupivacaine.

Interventions

  • DRUG Liposomal bupivacaine
  • DRUG Bupivacaine/epinephrine/dexamethasone

Study Locations (1)

California

  • Cedars Sinai Medical Center - Los Angeles

Trial Details

FieldValue
Enrollment Target 102 participants
Start Date 2018-10-23
Est. Completion 2019-10-29
Phase Phase 4
Cedars-Sinai Medical Center

339 total trials

What the finished NCT03723447 record still lists

NCT03723447 is an interventional study that assigns participants to a tested intervention. The registered 102 participants enrollment target is mid-sized for trials with a published cap, below the 1,544-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (93% lower).

The record links to 10 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 2 interventions - of which Liposomal bupivacaine is the first listed.

NCT03723447 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT03723447 about?

NCT03723447 is a clinical study titled "Intraoperative TAP Block With Bupivacaine/Dexamethasone Against Liposomal Bupivacaine (Exparel®)". Traditionally, opioids are heavily utilized in treating postoperative pain but they are associated with numerous side effects. The use of the transversus abdominis plane (TAP) blocks have become standard practice to extend the post-operative analgesic window and limit opioid use. A new liposomal-dep...

What is the current status of trial NCT03723447?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 102 participants. The study started on 2018-10-23. Estimated completion is 2019-10-29.

What conditions does trial NCT03723447 study?

This clinical trial studies the following conditions: Colorectal Cancer, Pain, Pain, Postoperative, Crohn Disease, Gastrointestinal Cancer.

What interventions are being tested in trial NCT03723447?

The interventions under investigation include: Liposomal bupivacaine (DRUG), Bupivacaine/epinephrine/dexamethasone (DRUG).

Who is sponsoring clinical trial NCT03723447?

This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03723447 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Colorectal Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03723447's enrollment target sits among peer trials

102 214th of 381 higher than 168 of 381 other Colorectal Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03704662 · 102 participants · NA

    Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma

  • NCT04174742 · 102 participants

    Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer

  • NCT04275362 · 102 participants

    Gait Analysis of a Lateral-Pivot Design Total Knee Replacement

  • NCT04541082 · 102 participants · Phase 1

    Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03723447, the US trial registry maintained by the National Library of Medicine. NCT03723447 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.